A Phase Ib/IIa Randomized, Placebo Controlled Study of the Safety and Efficacy of Once Daily Dosing of STP206 in Premature Very Low Birth Weight and Extremely Low Birth Weight Neonates

Trial Profile

A Phase Ib/IIa Randomized, Placebo Controlled Study of the Safety and Efficacy of Once Daily Dosing of STP206 in Premature Very Low Birth Weight and Extremely Low Birth Weight Neonates

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs STP 206 (Primary)
  • Indications Acute enterocolitis
  • Focus Adverse reactions
  • Sponsors Leadiant Biosciences
  • Most Recent Events

    • 02 Apr 2015 According to Sigma-Tau Pharmaceuticals, STP-206 received Orphan Drug Designation in U.S.
    • 09 Feb 2015 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019 as reported by ClinicalTrials.gov record.
    • 09 Feb 2015 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top